about
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer
P50
description
researcher (ORCID 0000-0003-1960-4552)
@en
name
Min Huang
@en
type
label
Min Huang
@en
prefLabel
Min Huang
@en
P31
P496
0000-0003-1960-4552